Key result
Among women with undifferentiated connective tissue disease, 79% of pregnancies resulted in live births, with miscarriages and stillbirths strongly associated with aPL and ENA antibodies (P<0.05).
Why the study?
Fetal, perinatal, and maternal outcomes in women diagnosed with UCTD needed investigation in a large multicentre cohort.
Cohort (n=133)
Yes
Women with UCTD have a high live birth rate (79%), but miscarriages and stillbirths are strongly associated with aPL and ENA antibodies, highlighting the need for specialist follow-up and antibody profiling during pregnancy planning.
May warrant specialist monitoring in antibody-positive UCTD pregnancies; leaves open whether targeted interventions improve outcomes.
OBJECTIVES: To investigate fetal/perinatal and maternal outcomes from a large multicentre cohort of women diagnosed with UCTD. METHODS: This multicentre retrospective cohort study describes the outcomes of 224 pregnancies in 133 consecutive women with a diagnosis of UCTD, positive for ANA and aged <45 years old at study inclusion. RESULTS: Of the 224 pregnancies analysed, 177 (79%) resulted in live births, 45 (20.1%) in miscarriages (defined as pregnancy loss before 12 weeks' gestation), 2 (0.9%) in stillbirths (pregnancy loss after 20 weeks' gestation) and 6 (2.7%) cases showed intrauterine growth restriction. Miscarriages and stillbirths were strongly associated with the presence of aPL and ENA antibodies (P < 0.05). Maternal pregnancy complications were as follows: 5 (2.2%) cases developed pre-eclampsia, 11 (4.9%) cases gestational hypertension and 12 (5.4%) cases gestational diabetes. Joint involvement represented the most frequent clinical manifestation of the cohort (57.9%), followed by RP (40.6%), photosensitivity (32.3%) and haematological manifestations (27.1%). The rate of disease evolution of our cohort from a diagnosis of UCTD to a diagnosis of definite CTD was 12% within a mean time of 5.3 ± 2.8 years. With a total follow-up after first pregnancy of 1417 patient-years, we observed the evolution to a defined CTD in one out of every 88 patient- years. CONCLUSION: In our multicentre cohort, women with UCTD had a live birth rate of 79%. Women with UCTD should be referred to specialist follow-up when planning a pregnancy. ENA profiling and aPL testing should be mandatory in this setting, and further therapeutic approaches and management should be planned accordingly.
No takes yet. Share an insight, caveat, or question.
Radin et al. (2019) conducted a cohort in Undifferentiated connective tissue disease (UCTD) (n=133). Undifferentiated connective tissue disease was evaluated on Live births. Among women with undifferentiated connective tissue disease, 79% of pregnancies resulted in live births, with miscarriages and stillbirths strongly associated with aPL and ENA antibodies (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: